ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Can IL-6 Predict Sarilumab Response?

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2019

Recent post-hoc analyses of two Phase 3 clinical trials show that RA patients with high interleukin 6 levels taking sarilumab experienced improved symptoms and less joint damage than those using other treatments…

Filed under:Drug Updates Tagged with:adalimumabMethotrexatesarilumab

How Advances in Artificial Intelligence May Aid Rheumatology

Richard Quinn  |  December 19, 2018

From digital scribes to predictive pharmacology—as artificial intelligence advances, technology has a lot to offer medicine. What opportunities lie ahead for rheumatologists and their patients?

Filed under:Technology Tagged with:appsartificial intelligenceelectronic health record (EHR)Technology

Carla Guggenheim, DO, Dances through the Pain

Carol Patton  |  December 18, 2018

Two years ago, Carla Guggen­heim, DO, a rheumatologist in private practice in Lansing, Mich., was recovering from extensive shoulder surgery when her dance teacher asked her to perform a complex Indian piece from the Bharatanatyam Repertory at a gala showcasing graduate dance students. Because of her surgery, Dr. Guggenheim agreed to dance only 90 seconds…

Filed under:AudioProfilesRheum After 5 Tagged with:Dr. Carla Guggenheim

Richard M. Silver, MD, in the Spotlight

Gretchen Henkel  |  December 18, 2018

The Division of Rheumatology and Immunology at the Medical University of South Carolina (MUSC), Charleston, was formally established in 1974 by its first division chief, E. Carwile LeRoy, MD. Twenty-one years later, when Richard M. Silver, MD, assumed leadership, the division had acquired international renown for its scleroderma research. Now, having just retired as division…

Filed under:Profiles Tagged with:Dr. Richard M. Silver

Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes

Larry Beresford  |  December 18, 2018

An analysis of treat-to-target therapy assessing two ultrasound definitions of remission for patients with early rheumatoid arthritis (RA) has concluded that using ultrasound remission as a target was not associated with better long-term outcomes for RA patients.1 Compared with MRI, ultrasound costs less, is more accessible and offers the ability to scan more joints in…

Filed under:Research RheumRheumatoid Arthritis Tagged with:Remission CriteriaUltrasound

The 2018 ARHP Merit Awards & ACR Distinguished Fellows

Carol Patton, with Keri Losavio  |  December 18, 2018

CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARHP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find interviews…

Filed under:AwardsMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)Daniel SchafferDanielle RiceDr. Ann Marie SzymanskiDr. Antonia ValenzuelaDr. April M. JorgeDr. Bella MehtaDr. Brittany AdlerDr. Carol A. OatisDr. Charles G. HelmickDr. Christina H. OpavaDr. DeAnna A. Baker FrostDr. Debbie Ehrmann-FeldmanDr. Marcela A. FerradaDr. Patrick R. WoodDr. Sara AlehashemiDr. Shudan WangHiral MasterJanalee TaylorLisa Robbins

How to Teach in the Inpatient Setting

Thomas R. Collins  |  December 18, 2018

CHICAGO—Teaching in the inpatient setting can be a tall task, hindered by a lack of time, an unpredictable environment and a variety of learners encountered at different levels. But a few techniques—based mainly on understanding who your students are and how they prefer to learn—can make a big difference, an expert said at the 2018…

Filed under:Education & TrainingMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetinginpatient teaching

Tips for Using Digital Health Tools

Thomas R. Collins  |  December 18, 2018

CHICAGO—Approximately 200,000 health apps are available through major app stores. Some offer real benefits, said Brennan Spiegel, MD, MSHS, director of health services research at Cedars-Sinai Health System, Los Angeles, Calif. But most, he told attendees at the 2018 ACR/ARHP Annual Meeting, are “rubbish.” “They do one or two things only—and generally not well,” he…

Filed under:AppsMeeting ReportsTechnology Tagged with:2018 ACR/ARHP Annual Meetingmobile appsTechnologywearable device

ACR Leaders Discuss E/M Coding Changes, Step Therapy & More

Thomas R. Collins  |  December 18, 2018

CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…

Filed under:Billing/CodingLegislation & AdvocacyMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingBiosimilarsE/M CodingH1B visasstep therapy

Bimekizumab Promising for PsA

Michele B. Kaufman, PharmD, BCGP  |  December 18, 2018

CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Bimekizumabpsoriatic arthritis

  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 328
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences